| Next 10 |
Ad
SGMO News and Press Sangamo Therapeutics Inc.
News | Sangamo Therapeutics Inc. (NASDAQ:SGMO)
-
2025-01-10 13:29:19 ET More on Intellia Therapeutics Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade) Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call...
-
2024-12-31 21:00:01 ET Summary Sangamo Therapeutics faces a major setback as Pfizer terminates their partnership for the hemophilia A gene therapy program, significantly impacting the share price. Despite positive Phase III results, Pfizer's exit raises concerns about competition,...
-
2024-12-31 09:55:29 ET More on Pfizer, Sangamo Therapeutics, etc. Pfizer: One Of The Next Big AI Winners Pfizer: Why I'm Staying On The Sidelines Pfizer: Time And Patience Ran Out (Rating Downgrade) Sangamo plunges 38% after Pfizer ends agreement on hemophili...
-
2024-12-30 16:38:33 ET More on Sangamo Therapeutics Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regu...
-
- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration partner Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine co...
-
2024-12-19 14:48:01 ET Summary Sangamo Therapeutics, Inc. received IND clearance to initiate a phase 1/2 study for ST-503 targeting idiopathic small fiber neuropathy, a type of chronic neuropathic pain condition. SGMO entered a deal with Astellas, allowing the use of its STAC-BBB ...
-
2024-12-19 08:49:40 ET DENVER, Colo., Dec 19, 2024 ( 247marketnews.com )- Sangamo Therapeutics (NASDAQ: SGMO ) entered into a license agreement granting Astellas worldwide exclusive license to leverage Sangamo’s neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which...
-
2024-12-19 07:50:27 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec....
-
2024-12-19 05:00:28 ET More on related stocks: Micron Technology, Inc. (MU) Post Earnings Q1 2025 Earnings Call Transcript Micron Technology, Inc. (MU) Q1 2025 Earnings Call Transcript Micron Technology, Inc. 2025 Q1 - Results - Earnings Call Presentation Mes...
-
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases PR Newswire - Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targe...
Stock Information
Get SGMO Alerts
News, Short Squeeze, Breakout and More Instantly...
Sangamo Therapeutics Inc. Company Name:
SGMO Stock Symbol:
NASDAQ Market:
Sangamo Therapeutics Inc. Website:
Ad
-
- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration partner Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine co...
-
2024-12-19 08:49:40 ET DENVER, Colo., Dec 19, 2024 ( 247marketnews.com )- Sangamo Therapeutics (NASDAQ: SGMO ) entered into a license agreement granting Astellas worldwide exclusive license to leverage Sangamo’s neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which...
-
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases PR Newswire - Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targe...